Browse > Article
http://dx.doi.org/10.4046/trd.2021.0087

Does the Use of Asthma-Controller Medication in Accordance with Guidelines Reduce the Incidence of Acute Exacerbations and Healthcare Costs?  

Lee, Suh-Young (Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center)
Kim, Kyungjoo (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Park, Yong Bum (Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine)
Yoo, Kwang Ha (Department of Internal Medicine, Konkuk University School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.85, no.1, 2022 , pp. 11-17 More about this Journal
Abstract
Background: In asthma, consistent control of chronic airway inflammation is crucial, and the use of asthma-controller medication has been emphasized. Our purpose in this study is to compare the incidence of acute exacerbation and healthcare costs related to the use of asthma-controller medication. Methods: By using data collected by the National Health Insurance Review and Assessment Service, we compared one-year clinical outcomes and medical costs from July 2014 to June 2015 (follow-up period) between two groups of patients with asthma who received different prescriptions for recommended asthma-controller medication (inhaled corticosteroids or leukotriene receptor antagonists) at least once from July 2013 to June 2014 (assessment period). Results: There were 51,757 patients who satisfied our inclusion criteria. Among them, 13,702 patients (26.5%) were prescribed a recommended asthma-controller medication during the assessment period. In patients using a recommended asthma-controller medication, the frequency of acute exacerbations decreased in the follow-up period, from 2.7% to 1.1%. The total medical costs of the controller group decreased during the follow-up period compared to the assessment period, from $3,772,692 to $1,985,475. Only 50.9% of patients in the controller group used healthcare services in the follow-up period, and the use of asthma-controller medication decreased in the follow-up period. Conclusion: Overall, patients using a recommended asthma-controller medication showed decreased acute exacerbation and reduced total healthcare cost by half.
Keywords
Asthma; Disease Management; Health-Effect Assessment; Costs and Cost Analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and health care utilization in Asia-Pacific countries. Respir Med 2014;108:271-7.   DOI
2 Jacob C, Bechtel B, Engel S, Kardos P, Linder R, Braun S, et al. Healthcare costs and resource utilization of asthma in Germany: a claims data analysis. Eur J Health Econ 2016;17:195-201.   DOI
3 Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, et al. Poor control increases the economic cost of asthma: a multicentre population-based study. Int Arch Allergy Immunol 2006;141:189-98.   DOI
4 Williams SA, Wagner S, Kannan H, Bolge SC. The association between asthma control and health care utilization, work productivity loss and health-related quality of life. J Occup Environ Med 2009;51:780-5.   DOI
5 Frey U. Predicting asthma control and exacerbations: chronic asthma as a complex dynamic model. Curr Opin Allergy Clin Immunol 2007;7:223-30.   DOI
6 DiMango E, Rogers L, Reibman J, Gerald LB, Brown M, Sugar EA, et al. Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy. Ann Am Thorac Soc 2018;15:955-61.   DOI
7 Laforest L, Licaj I, Devouassoux G, Chatte G, Belhassen M, Van Ganse E, et al. Relative exposure to controller therapy and asthma exacerbations: a validation study in community pharmacies. Pharmacoepidemiol Drug Saf 2014;23:958-64.   DOI
8 Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.   DOI
9 Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017;32:718-28.   DOI
10 Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-208.
11 Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas medicaid patients with persistent asthma. J Manag Care Spec Pharm 2015;21:1124-32.
12 Kang HR, Song HJ, Nam JH, Hong SH, Yang SY, Ju S, et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open 2018;8:e020825.   DOI
13 Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, et al. Korean Asthma Guideline 2014: summary of major updates to the Korean asthma guideline 2014. Tuberc Respir Dis 2016;79:111-20.   DOI
14 Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-45.   DOI
15 Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995;108:1228-34.   DOI
16 Lai CK, De Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB, et al. Asthma control in the Asia-Pacific region: the asthma insights and reality in Asia-Pacific study. J Allergy Clin Immunol 2003;111:263-8.   DOI
17 Hedlin G, Bush A, Lodrup Carlsen K, Wennergren G, De Benedictis FM, Melen E, et al. Problematic severe asthma in children, not one problem but many: a GA2LEN initiative. Eur Respir J 2010;36:196-201.   DOI
18 Chou CL, Perng DW, Lin TL, Lin AM, Chen TJ, Wu MS, et al. Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. Clin Ther 2015;37:2275-85.   DOI
19 Kim SR, Lee YC, Sung MJ, Bae HW. Current epidemiological data on asthma management in South Korea from qualitative assessment of asthma management by Health Insurance Review and Assessment Service (HIRA). Tuberc Respir Dis 2017;80:221-5.   DOI
20 van de Veen W, Wirz OF, Globinska A, Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr Opin Immunol 2017;48:74-81.   DOI
21 Dean BB, Calimlim BM, Kindermann SL, Khandker RK, Tinkelman D. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009;46:861-6.   DOI
22 Meng YY, Babey SH, Hastert TA, Lombardi C, Brown ER. Uncontrolled asthma means missed work and school, emergency department visits for many Californians. Policy Brief UCLA Cent Health Policy Res 2008;(PB2008-2):1-8.
23 Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42.   DOI
24 Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest 2014;145:787-93.   DOI